This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Dyax Corp. Announces Appointment Of Todd Bazemore As Chief Commercial Officer

Stocks in this article: DYAX

Dyax Corp. (NASDAQ: DYAX) announced today the appointment of Todd Bazemore as Executive Vice President and Chief Commercial Officer. Mr. Bazemore will be responsible for leading Dyax’s commercial organization which currently markets KALBITOR ® (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older.

Mr. Bazemore joins Dyax as a pharmaceutical executive with 20 years of leadership and commercial operating experience in sales, marketing and managed markets. He most recently served as Vice President, Managed Markets at Sunovion Pharmaceuticals, Inc. (formerly Sepracor). Prior to this, he served as Vice President of Sales and Marketing leading the Sunovion Respiratory Business Unit where he was responsible for the overall strategic direction and financial performance of the unit which generated $680 million in annual revenue. During his time at Sunovion, Mr. Bazemore held several roles of increasing responsibility in marketing and sales leadership including Vice President of Sales for the Pinnacle Sales Team, which was responsible for promoting OMNARIS ®, as well as LUNESTA ®, one of the most successful pharmaceutical product launches in the U.S. He also went on to build and oversee multiple sales and marketing teams responsible for several successful new product launches including BROVANA ® and XOPENEX ®.

“Todd is a senior healthcare executive with two decades of commercial experience in both primary care and specialty markets, which makes him ideally suited to lead our commercial team,” said Gustav Christensen, President and Chief Executive Officer of Dyax. “His strong track record of strategic leadership, operational execution, and launching and developing brands will be highly valuable as we aim to grow our KALBITOR business and as we develop plans for how to optimize the value of DX-2930 which is currently in clinical development.”

Mr. Bazemore stated, “It's a privilege to join the Dyax team during this important time as we continue to successfully commercialize KALBITOR and develop our future plans for DX-2930. I'm excited about the opportunity we have to truly help both the patients suffering from HAE and the physicians that treat them.”

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,716.33 +30.60 0.17%
S&P 500 2,052.36 +3.64 0.18%
NASDAQ 4,698.7190 +23.0070 0.49%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs